The National Drug Discovery Centre features the latest in robotic high-throughput screening technologies with a highly modular system that can be customised according to project needs.
Our platforms
Our lab is equipped with two ultra-high throughput robotic platforms for both biochemical and cell-based assays. These configurable platforms can support diverse assay readout technologies, including high-throughput flow cytometry, high-content imaging, whole-plate fluorometric imaging and traditional plate-reader screens.
Readers
We have four types of readers, which can be docked to a robotic platform or used independently.
- High-content imaging: PerkinElmer Opera Phenix confocal imaging system with high-throughput by simultaneous acquisition
- Multi-mode microplate reader: BMG PHERAstar FSX
- Automated FACS: Intellicyt iQue Screener PLUS automated flow cytometry for phenotypic screens
- Whole-plate fluorometric imaging: FLIPR Penta high-throughput cellular screening system
Compound library
We offer users access to a diverse screening collection containing more than 100,000 high-quality and lead-like compounds.
We also welcome users who wish to provide their own libraries or source alternative collections. Compounds Australia has a diverse range of compound collections that can be plated in HTS format and used for your screen.
Assay capabilities
We can screen for a very large diversity of target classes. Users provide their own assay protocol and specific materials, such as cell lines or proteins. If your assay has been demonstrated in 96-well format and meets minimum robustness, signal-to-background and component-stability requirements, our expert staff will miniaturise and adapt it to run on our high-throughput platform.